Introduction: MMPs, ADAMs/ADAMTSs research products to achieve big dream

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 7, 2012, Pages 688-706

  Okazaki, Isao ^a   Nabeshima, Kazuki ^b  

^a INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

A disintegrin and metalloproteinase (ADAM); A disintegrin and metalloproteinase with thrombospondin motif (ADAMTS); Anti cancer agents; Cancer invasion; Cancer metastasis; Cancer treatment; Matrix metalloproteinase (MMP); Tissue inhibitor of metalloproteinases (TIMP)

Indexed keywords

2 (3 METHOXY PHENYL) 6,7 METHYLENEDIOXO QUINOLINE 4 ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ACACETIN; ANTHOCYANIN; ANTINEOPLASTIC AGENT; CAPSAICIN; CARBOPLATIN; CISPLATIN; CORDYCEPIN; CURCUMIN; DOXORUBICIN; EUGENOL; FASUDIL; IMATINIB; MATRIX METALLOPROTEINASE; MELATONIN; METFORMIN; MONOCLONAL ANTIBODY 4C5; OSTHOLE; OXYTHIAMINE; PHENETHYL ISOTHIOCYANATE; PHYTIC ACID; PIOGLITAZONE; PIPERINE; PROPOFOL; RESVERATROL; THIOCTIC ACID; UKRAIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL MIGRATION; GENE STRUCTURE; HEAD AND NECK CARCINOMA; HUMAN; INFLAMMATION; METASTASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHYLLANTHUS URINARIA; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; VASCULARIZATION;

EID: 84866433489     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012802650200     Document Type: Article

References (209)

1. Gross, G.; Lapiere, C. M. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc. Natl. Acad. Sci. USA, 1962, 48(June 15), 1014-1022.
2. Lopez-Otin, C.; Bond, J.S. Proteases: multifunctional enzymes in life and disease. J. Biol. Chem., 2008, 283(45): 30433-30437.
3. Sterchi, E. E.; Stocker, W.; Bond, J. S. Meprins, membrane-bound and secreted astacin metalloproteinases. Mol. Aspects Med., 2008, 29(5), 309-328.
4. Stocker, W.; Baumann, U.; Reinemer, P.; Gomis-Ruth, F. X.; McKay, D. B.; Bode, W. The metzincins - topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zincpeptidases. Protein Sci., 1995, 4(5), 823-840.
5. Jackson, B. C.; Nebert, D. W.; Vasiliou, V. Update of human and mouse matrix metalloproteinase families. Hum. Genomics, 2010, 4(3), 194-201.
6. Nagase, H.; Woessner, J. F. Matrix metalloproteinases. J. Biol. Chem., 1999, 274(31), 21491-21494.
7. Lohi, J.; Wilson, C. L.; Roby, J. D.; Parks, W. D. Epilysin, a novel human metalloproteinases (MMP-28) expressed in tetstis and keratinocytes and in response to injury. J. Biol Chem., 2001, 276(13), 10134-10144.
8. Seiki, M. Membrane-type matrix metalloproteinases. APMIS, 1999, 107(1), 137-143.
9. Nabeshima, K.; Inoue, T.; Shimao, Y.; Sameshima, T. In: Extracellular Matrix and the Liver; Okazaki, I.; Ninomiya, Y.; Friedman, S.; Tanikawa, K., Ed.; Academic Press, New York, 2003; pp. 251-275.
10. Hayakawa, T.; Yamashita, K. In: Extracellular Matrix and the Liver; Okazaki, I; Ninomiya, Y.; Friedman, S.; Tanikawa, K., Ed.; Academic Press, New York, 2003; pp. 309-329.
11. Black, R. A.; White, J. M. ADAMs: focus on the protease domain. Curr. Opin. Cell Biol., 1998, 10(5), 654-659.
12. Mochizuki, S.; Okada, Y. ADAMs in cancer cell proliferation and progression. Cancer Sci., 2007, 98(5), 621-628.
13. Shiomi, T.; Lemaitre, V.; D'Armiento, J.; Okada, Y. Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases. Pathol. Int., 2010, 60(7), 477-496.
14. Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, 2010, 141(1), 52-67.
15. Chambers, A. F.; Matrisian, L. M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst., 1997, 89(17), 1260-1270.
16. Pei, D.; Kang, T.; Qi, H. Cysteine array matrix metalloproteinases (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation. J. Biol. Chem., 2000, 275(43), 33988-33997.
17. Murphy, G.; Atkinson, S.; Ward, R.; Gavrilovic, J.; Reynolds, J. J. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann. N. Y. Acad. Sci., 1992, 667(Dec 4), 1-12.
18. Okazaki, I.; Brinckerhoff, C. E.; Sinclair, J. R.; Sinclair, P. R.; Bonkowsky, H. L.; Harris, E. D., Jr. Iron increases collagenase production by rabbit synovial fibroblasts. J. Lab. Clin. Med., 1981, 97(3), 396-402.
19. Auble, D. T.; Brinckerhoff, C. E. The AP-1 sequence is necessary but not sufficient for phorbol induction of collagenase in fibroblasts. Biochemistry, 1991, 30(18), 4629-4635.
20. Armstrong, D. A.; Phelps, L. N.; Vincenti, M. P. CCAAT enhancer binding protein-beta regulates matrix metalloproteinase-1 expression in interleukin-1beta-stimulated A549 lung carcinoma cells. Mol. Cancer Res., 2009, 7(9), 1517-1524.
21. Sato, H.; Takino, H.; Okada, Y.; Cao, J.; Yamamoto, E.; Seiki, M. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature, 1994, 370(6484), 61-65.
22. Will, H.; Atkinson, S. J.; Butler, G. S.; Smith, B.; Murphy, G. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J. Biol. Chem., 1996, 271(29), 17119-17123.
23. Kinoshita, T.; Sato, H.; Okada, A.; Ohuchi, E.; Imai, K.; Okada, Y.; Seiki, M. TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J. Biol. Chem., 1998, 273(26), 16098-16103.
24. Knauper, V.; Will, H.; Lopez-Otin, C.; Smith, B.; Atkinson, S. J.; Stanton, H.; Hembry, R. M.; Murphy, G. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J. Biol. Chem., 1996, 271(29), 17124-17131.
25. Knauper, V.; Smith, B.; Lopez-Otin, C.; Murphy, G. Activation of progelatinase B (proMMP-9 by active collagenase-3 (MMP-13). Eur. J. Biochem., 1997, 248(2), 369-373.
26. Ohuchi, E.; K Imai; Fujii, Y.; Sato, H.; Seiki, M.; Okada, Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J. Biol. Chem., 1997, 272(4), 2446-2451.
27. English, W. R.; Puentes, X. S.; Freije, J. M. P.; Knauper, V.; Amour, A.; Merryweather, A.; Lopez-Otin, C.; Murphy, G. Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor-alpha convertase activity but does not activate pro-MMP2. J. Biol. Chem., 2000, 275(19), 14046-14055.
28. Itoh, Y.; Kajita, M.; Kinoh, H.; Mori, H.; Okada, A.; Seiki, M. Membrane type 4 matrix metalloproteinase (MT4-MMP, MMP-17) is a glycosylphosphatidylinositol-anchored proteinase. J. Biol. Chem., 1999, 48(48), 34260-34266.
29. Edwards, D. R.; Handsley, M. M.; Pennington, C. J. The ADAM metalloproteinases. Mol. Aspects Med., 2008, 29(5), 258-289.
30. Tang, B. L. ADAMTS: a novel family of extracellular matrix proteases. Int. J. Biochem. Cell Biol., 2001, 33(1), 33-44.
31. Moss, M. L.; Jin, S-L. C.; Milla, M. E.; Burkhart, W.; Varter, H. L.; Chen, W. J.; Clay, W. C.; Didsbury, J. R. Cloning a disintegrin metalloproteinase that processes precursor tumor-necrosis factoralpha. Nature, 1997, 385(6618), 733-736.
32. Peschon, J. J; Slack, J. L.; Reddy, P.; Stocking, K. L.; Sunnarborg, S. W.; Lee, D. C.; Russell, W. E.; Castner, B. J.; Johnson, R. S.; Fitzner, J. N.; Boyce, R. W.; Nelson, N.; Kozlosky, C. J.; Wolfson, M. F.; Raush, C. T.; Cerreti, D. P.; Paxton, R. J.; March, C. J.; Black, R. A. An essential role for ectodomain shedding in mammalian development. Science, 1998, 282(5392), 1281-1284.
33. Primakoff, P.; Myles, D. G. The ADAM gene family: surface proteins with adhesion and protease activity. Trends Genet., 2000, 16(2), 83-87.
34. Qi, H.; Rand, M. D.; Wu, X.; Sestan, N.; Wang, W.; Rakic, P.; Xu, T.; Artavanis-Tsakonas, S. Processing of the notch ligand delta by the metalloprotease Kuzbanian. Science, 1999, 283(5398), 91-94.
35. Izumi, Y.; Hirata, M.; Hasuwa, H.; Iwamoto, R.; Umata, T.; Miyado, K.; Tamai, Y.; Kurisaki, T.; Sehara-Fujisawa, A.; Ohno, S.; Mekada, E. A metalloprotease-disintegrin, MDC9/meltringamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J., 1998, 17(24), 7260-7272.
36. Yagami-Hiromasa, T.; Sato, T.; Kurisaki, T., Kamijo, K.; Nabeshima, Y.; Fujisawa-Sehara, A. A metalloprotease-disintegrin participating in myoblast fusion. Nature, 1995, 377(6550), 652-656.
37. Howard, E. W; Bullen, E. C.; Banda, M. J. Regulation of the autoactivation of human 72-kDa progelatinase by tissue inhibitor of metalloproteinases-2. J. Biol. Chem., 1991, 266(20), 13064-13069.
38. Ward, R. V.; Hembry, R. M.; Reynolds, J. J.; Murphy, G. The purification of tissue inhibitor of metalloproteinases-2 from its 72 kDa progelatinase complex. Demonstration of the biochemical similarities of tissue inhibitor of metalloproteinase-2 and tissue inhibitor of metalloproteinase-1. Biochem. J., 1991, 278(Pt 1), 179-187.
39. Nguyen, Q.; Willenbrock, F.; Cockett, M. L.; O'Shea, M.; Docherry, A. J. P.; Murphy, G. Different domain interactions are involved in the binding of tissue inhibitors of metalloproteinases to stromelysin-1 and gelatinase A. Biochemistry, 1994, 33(8), 2089-2095.
40. Apte, S. S.; Olsen, B. R.; Murphy, G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitoryactivities define the distinct TIMP gene family. J. Biol. Chem., 1995, 270(24), 14313-14318.
41. Knauper, V.; Lopez-Otin, C.; Smith, B.; Knight, G.; Murphy, G. Biochemical characterization of human collagenase-3. J. Biol. Chem., 1996, 271(3), 1544-1550.
42. Kinoshita, T.; Sato, H.; Takino, T.; Itoh, M.; Akizawa, T.; Seiki, M. Processing of a precursor of 72-kilodalton type IV collagenase/gelatinase A by a recombinant membrane-type 1 matrix metalloproteinase. Cancer Res., 1996, 56(11), 2535-2538.
43. Amour, A.; Slocombe, P. M.; Webster, A.; Butler, M.; Knight, C. G.; Smith, B. J.; Stephens, P. E.; Shelley, C.; Hutton, M.; Knauper, V.; Dochertty, A. J. P.; Murphy, G. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett., 1998, 435(1), 39-44.
44. Amour, A.; Knight, C. G.; Webster, A.; Slocombe, P. M.; Stephens, P. E.; Knauper, V.; Dochetty, A. J. P.; Murphy, G. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett. 2000, 473(3), 275-279.
45. Loechel, F.; Fox, J. W.; Murphy, G.; Albrechtsen, R.; Wewer, U. M. ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem. Biophys. Res. Commun.2000, 278(3), 511-515.
46. Hashimoto, G.; Aoki, T.; Nakamura, H.; Tanzawa, K; Okada, Y. Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4). FEBS Lett.2001, 494(3), 192-195.
47. Kashiwagi, M.; Tortorella, M.; Nagase, H.; Brew, K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J. Biol. Chem., 2001, 276(16), 12501-12504.
48. Campbell, C. E.; Flenniken, A. M.; Skup, D.; Williams, B. R. Identification of a serum- and phorbol ester-responsive element in the murine tissue inhibitor of metalloproteinase gene. J. Biol. Chem., 1991, 266(11), 7199-7206.
49. Docherty, A. J. P.; Lyons, A.; Smith, B. J.; Wright, E. M., Stephens, P. E.; Harris, T. J. R.; Murphy, G.; Reynolds, J. J. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature, 1985, 318(6041), 66-69.
50. Gasson, J. C.; Golde, D. W.; Kaufman, S. E.; Westbrook, C. A.; Hewich, R. M.; Kaufman, R. J.; Wong, G. G.; Temple, P. A.; Leary, A. C.; Brown, E. L.; Orr, E. C.; Clark, S. C. Molecular characterization and expression of the gene encoding human erythroid-potentiating activity. Nature, 1985, 315(6022), 768-771.
51. Westbrook, C. A.; Gasson, J. C.; Gerber, S. E.; Selsted, M. E.; Golde, D. W. Purification and characterization of human Tlymphocyte-derived erythroid-potentiating activity. J. Biol. Chem., 1984, 259(16), 9992-9996.
52. Avalos, B. R.; Kaufman, S. E.; Tomonaga, M.; Williamas, R. E.; Golde, D. W.; Gasson, J. C. K562 cells produce and respond to human erythroid-potentiating activity. Blood, 1988, 71(6), 1720-1725.
53. Stetler-Stevenson, W. G.; Bersch, N.; Golde, D. W. Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity. FEBS Lett., 1992, 296(2), 231-234.
54. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2002, 2(3), 161-174.
55. Sternlicht, M. D.; Werb, Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol., 2001, 17, 463-516.
56. Weiss, S. J.; Peppin, G.; Ortiz, X.; Ragsdale, C.; Test, S. T. Oxidative autoactivation of latent collagenase by human neutrophils. Science, 1985, 227(4688), 747-749.
57. Fu, X.; Kassim, S. Y.; Parks, W. C.; Heinecke, J. W. Hypochlorous acid generated by myeloperoxidase modifies adjacent tryptophan and glycine residues in the catalytic domain of matrix metalloproteinase-7 (matrilysin): an oxidative mechanism for restraining proteolytic activity during inflammation. J. Biol. Chem., 2003, 278(31), 28403-28409.
58. Okazaki, I.; Wada, N.; Nakano, M.; Saio, A.; Takasaki, K.; Doi, M.; Kameyama, K.; Otani, Y.; Kubochi, K.; Niioka, M.; Watanabe, T. Difference in gene expression for matrix metalloproteinase-1 between early and advanced hepatocellular carcinomas. Hepatology, 1997, 25(3), 580-584.
59. Sugioka, Y.; Watanabe, T.; Inagaki, Y.; Kushida, M.; Niioka, M.; Endo, H.; Higashiyama, R.; Okazaki, I. C-Jun NH2-terminal kinase pathway is involved in constitutive matrix metalloproteinase-1 expression in a hepatocellular carcinoma-derived cell line. Int. J. Cancer, 2004, 109(6), 867-874.
60. Cross, T. G.; Scheel-Toellner, D.; Henriquez, N. V.; Deacon, E.; Salmon, M.; Lord, J. M. Serine/threonine protein kinases and apotosis. Exp. Cell Res.2000, 256(1), 34-41.
61. Johnson, G. L.; Lapadat, R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 2002, 298(5600), 1911-1912.
62. Johansson, N.; Ala-Aho, R.; Uitto, V.; Grenman, R.; Fusenig, N. E.; Lopez-Otin, C.; Kahari, V. M. Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase. J. Cell Sci., 2000, 113.
63. Ishii, Y.; Ogura, T.; Tatemichi, M.; Fujisawa, H.; Otsuka, M.; Esumi, H. Induction of matrix metalloproteinase gene transcription by nitric oxide and mechanisms of MMP-1 gene induction in human melanoma cell lines. Int. J. Cancer, 2003, 103(2), 161-168.
64. Tower, G. B.; Coon, C. C.; Benbow, U.; Vincenti, M. P.; Brinkerhoff, C. E. Erk 1/2 differentially regulates the expression from the 1G/2G single nucleotide polymorphism in the MMP-1 promoter in melanoma cells. Biochim.Biophys.Acta, 2002, 1586(3), 265-274.
65. Davidson, B.; Givant-Horwitz, V.; Lazarovici, P.; Risberg, B.; Nesland, J. M.; Trope, C. G.; Schaefer, E.; Reich, R. Matrix metalloproteinases (MMP, EMMPRIN (extracellular matrix metalloproteinases inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma. Clin. Exp. Metastasis, 2003, 20(7), 621-631.
66. Huntington, J. T.; Shields, J. M.; Der, C. J.; Wyatt, C. A.; Benbow, U.; Slingluff, C. L., Jr.; Brinckerhoff, C. E. Overexpression of collagenase-1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J. Biol. Chem., 2004, 279(32), 33168-33176.
67. Junttila, M. R.; AlaAho, R.; Jokilehto, T.; Peltonen, J.; Kallajoki, M.; Grenman, R.; Jaakkola, P.; Westermarck, J.; Kahari, V. M. P38alpha and p38delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. Oncogene, 2007, 26(36), 5267-5279.
68. Endo, H.; Watanabe, T.; Sugioka, Y.; Niioka, M.; Inagaki, Y.; Okazaki, I. Activation of two distinct MAPK pathways governs constitutive expression of matrix metalloproteinase-1 in human pancreatic cancer cell line. Int. J. Oncol., 2009, 35(6), 1237-1245.
69. Rutter, J. L.; Benbow, U.; Coon, C. L.; Brinckerhoff, C. E. Celltype specific regulation of human interstitial collagenase-1 gene expression by interleukin-1 beta (IL-1 beta) in human fibroblasts and BC-8701 breast cancer cells. J. Cell Biochem., 1997, 66(3), 322-336.
70. Westermarck, J.; Kahari, V. M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J., 1999, 13(8), 781-792.
71. Sato, N.; Maehara, N.; Su, G. H.; Goggins, M. Effects of 5-aza-2'- deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J. Natl. Cancer Inst., 2003, 95(4), 327-330.
72. Rupp, P. A.; Visconti, R. P.; Czirok, A.; Cheresh, D. A.; Little, C. D. Matrix metalloproteinase 2-integrin alpha(v)beta3 binding is required for mesenchymal cell invasive activity but not epithelial locomotion: a computational time-lapse study. Mol. Biol. Cell, 2008, 19(12), 5529-5540.
73. Sabeh, F.; Ota, I.; Holmbeck, K.; Birkedal-Hansen, H.; Soloway, P.; Balbin, M.; Lopez-Otin, C.; Shapiro, S.; Inada, M.; Krane, S. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J. Cell Biol.,2004, 167(4), 769-781.
74. Sabeh, F.; Shimizu-Hirota, R.; Weiss, S. J. Protease-dependent versus -independent cancer cell invasion programs: thre edimensional amoeboid movement revisited. J. Cell Biol., 2009, 185(1), 11-19.
75. Wolf, K.; Wu, Y. I.; Liu, Y.; Geiger, J.; Tam, E.; Overall, C.; Stack, M. S.; Friedl, P. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat. Cell Biol.2007, 9(8), 893-904.
76. Friedl, P.; Wolf, K. Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Res., 2008, 68(18), 7247-7249.
77. Brinkmann, V.; Reichard, U.; Goosman, C.; Fauler, B.; Uhiemann, Y.; Weiss, D. S.; Weinrauch, Y.; Zychlinsky, A. Neutrophil extracellular traps kill bacteria. Science, 2004, 303(5663), 1532-1535.
78. Lin, W. W.; Karin, M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 2007, 117(5), 1175-1183.
79. Manicone, A. M.; McGuire, J. K. Matrix metalloproteinases as modulators of inflammation. Semin. Cell Dev. Biol., 2008, 19(1), 34-41.
80. Luo, J. L.; Maeda, S.; Hsu, L. C.; Yagita, H.; Karin, M. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNF alpha to TRAIL-mediated tumor regression. Cancer Cell, 2004, 6(3), 297-305.
81. Pinilla, S.; Alt, E.; Abdul Khalek, F. J.; Jotzu, C.; Muehlberg, F.; Beckmann, C.; Song, Y. H. Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Lett., 2009, 284(1), 80-85.
82. Motrescu, E. R.; Rio, M. C. Cancer cells, adipocytes and matrix metalloproteinase 11: a vicious tumor progression cycle. Biol. Chem., 2008, 389(8), 1037-1041.
83. McQuibban, G. A.; Gong, J. H.; Wong, J. P.; Wallace, J. L.; Clark-Lewis, I.; Overall, C. M. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood, 2002, 100(4), 1160-1167.
84. Liotta, L. A.; Tryggvason, K.; Garbisa, S.; Hart, I.; Foltz, C. M.; Shafie, S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature, 1980, 284(5751), 67-68.
85. Deryugina, E. I.; Bourdon, M. A.; Luo, G.-X.; Reisfeld, R. A.; Strongin, A. Matrix metalloproteinase-2 activation modulates glioma cell migration. J. Cell Sci., 1997, 110(Pt 19), 2473-2482.
86. George, S. J.; Johnson, J. L.; Angelini, G. D.; Newby, A. C.; Baker, A. H. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Gene Ther. 1998, 9(6), 867-877.
87. Hiraoka, N.; Allen, E.; Apel, I. J.; Gyetko, M. R.; Weiss, S. J. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell, 1998, 95(3), 365-377.
88. Coussens, L. M.; Werb, Z. Inflammation and cancer. Nature, 2002, 420(6917), 860-867.
89. Friedl, P.; Brocker, E. B. The biology of cell locomotion within three-dimensional extracellular matrix. Cell Mol. Life Sci. 2000, 57(1), 41-64.
90. Massague, J. TGFbeta in cancer. Cell, 2008, 134(2), 215-230.
91. Yu, Q.; Stamenkovic, I. Cell surface-localized marix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000, 14(2), 163-176.
92. Mu, D.; Cambier, S.; Fjellbirkeland, L.; Baron, J.L.; Munger, J.S.; Kawakatsu, H.; Sheppard, D.; Broaddus, V. C.; Nishimura, S. L. The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J. Cell Biol. 2002, 157(3), 493-507.
93. Cowden Dahl, K. D.; Symowicz, J.; Ning, Y.; Gutierrez, E.; Fishman, D. A.; Adley, B. P.; Stack, M. S.; Hudson, L. G. Matrix metalloproteinase 9 is a mediator of epidermal growth factordependent e-cadherin loss in ovarian carcinoma cells. Cancer Res. 2008, 68(12), 4606-4613.
94. Maretzky, T.; Reiss, K.; Ludwig, A.; Buchholz, J.; Scholz, F.; Proksch, E.; de Strooper, B.; Hartmann, D.; Saftig, P. ADAM 10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc. Natl. Acad. Sci. USA 2005, 102(26), 9182-9187.
95. Schulte, M.; Reiss, K.; Lettau, M.; Maretzky, T.; Ludwig, A.; Hartmann, D.; de Strooper, B.; Janssen, O.; Saftig, P. ADAM 10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. Cell Death Differ. 2007, 14(5), 1040-1049.
96. Waldhauer, I.; Goehlsdorf, D.; Gieseke, F.; Weinschenk, T.; Wittenbrink, M.; Ludwig, A.; Stevanovic, S.; Rammensee, H. G.; Steinie, A. Tumor-associated MICA is shed by ADAM proteases. Cancer Res. 2008, 6815, 6368-6376.
97. Butcher, D. T.; Alliston, T.; Weaver, V. M. A tense situation: forcing tumour progression. Nat. Rev. Cancer 2009, 9(2), 108-122.
98. Zhang, X.; Halvorsen, K.; Zhang, C. Z.; Wong, W. P.; Springer, T. A. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science 2009, 324(5932), 1330-1334.
99. Smith, M. L.; Gourdon, D.; Little, W. C.; Kubow, K. E.; Eguiluz, R. A.; Luna-Morris, S.; Vogel, V. Force-induced unfolding of fibronectin in the extracellular matrix of living cells. PLoS. Biol. 2007, 5(10), e268.
100. Padera, T. P.; Kadambi, A.; di Toaso, E.; Carreira, C. M.; Brown, E. B.; Boucher, Y.; Choi, N. C.; Mathisen, D.; Wain, J.; Mark, E. J., Munn, L. L.; Jain, R. K. Lymphatic metastasis in the absence of functional intratumor lympahtics. Science 2002, 296(5574), 1883-1886.
101. Shapiro, S. D. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr.Opin. Cell Biol. 1998, 10(5), 602-608.
102. Itoh, T.; Tanioka, M.; Yoshida, H.; Yoshioka, T.; Nishimoto, H.; Itohara, S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998, 58(5), 1048-1051.
103. Bergers, G.; Brekken, R.; McMahon, G.; Vu, T. H.; Itoh, T.; Tamaki, K.; Tanzawa, K.; Thorpe, P.; Itohara, S.; Werb, Z.; Hanahan, D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000, 2(10), 737-744.
104. Ahn, G. O.; Brown, J. M. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008, 13(3), 193-205.
105. Ardi, V. C.; Van den Steen, P. E.; Opdenakker, G.; Schweighofer, B.; Deryugina, E. I.; Quigley, J. P. Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGFR-2)/FGFR-2 pathway. J. Biol. Chem. 2009, 284(38), 25854-25866.
106. Huang, Y.; Song, N.; Ding, Y.; Yuan, S.; Li, X.; Cai, H.; Shi, H.; Luo, Y. Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Res. 2009, 69(19), 7529-7537.
107. Biswas, C. Tumor cell stimulation of collagenase production by fibroblasts. Biochem. Biophy. Res. Commun., 1982, 109(3), 1026-1034.
108. Nabeshima, K.; Iwasaki, H.; Koga, K.; Hojo, H.; Suzumiya, J.; Kikuchi, M. Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol. Int. 2006, 56(7), 359-367.
109. Smriti, M.; Agraval, V.; Yong, W. The many faces of EMMPRIN - roles in neuroinflammation. Biochim. Biophy. Acta 2011, 1812(2), 213-219.
110. Nabeshima, K.; Kataoka, H.; Toole, B. P.; Koono, M. In: Collagenases; Hoeffler, W. K., Ed.; Landes Company, Austin, TX, 1999, pp. 91-113.
111. Sameshima, T.; Nabeshima, K.; Toole, B. P.; Yokogami, K.; Okada, Y.; Goya, T.; Koono, M.; Wakisaka, S. Expression of emmprin (CD147), a cell surface inducer of matrixmetalloproteinases, in normal human brain and gliomas. Int. J. Cancer 2000, 88(1), 21-27.
112. Egawa, N.; Koshikawa, N.; Tomari, T.; Nabeshima, K.; Isobe, T.; Seiki, M. Membrane type 1 matrix metalloproteinase (MT1-MMP/MMP-14) cleaves and releases a 22-kDa extracellular matrix metalloproteinase inducer (EMMPRIN) fragment from tumor cells. J. Biol. Chem. 2006, 281(49), 37576-37585.
113. Muraoka, K.; Nabeshima, K.; Murayama, T.; Biswas, C.; Koono, M. Enhanced expression a tumor-cell-derived collagenasestimulatory factor in urothelial carcinoma: its usefulness as a tumor marker for bladder cancers. Int. J. Cancer 1993, 55(1), 19-26.
114. Polette, M.; Gilles, C.; Marchand, V.; Lorenzato, M.; Toole, B. P.; Tournier, J. M.; Zucker, S.; Birembaut, P. Tumor collagenase stimulatory factor (TCSF) expression and localization in human lung and breast cancers. J. Histochem. Cytochem. 1997, 45(5), 703-709.
115. Caudroy, S.; Pollete, M.; Tournier, J. M.; Burlet, H.; Toole, B.; Zucker, S.; Birembaut, P. Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in bronchopulmonary and breast lesions. J. Histoche. Cytochem. 1999, 47(12), 1575-1580.
116. Dallberg, K.; Eriksson, E.; Enberg, U.; Kjellman, M.; Backdahl, M. Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correction with invasive growth of breast cancer. World J. Surg. 2000, 24(3), 334-340.
117. Bordador, L. C.; Li, X.; Toole, B.; Chen, B.; Regezi, J.; Zardi, L.; Hu, Y.; Ramos, D. M. Expression of emmprin by oral squamous cell carcinoma. Int. J. Cancer 2000, 85(3), 347-352.
118. van den Oord, J. J.; Paemen, L.; Opdenakker, G.; De Wolf-Peeters, C. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am. J. Pathol. 1997, 151(3), 665-670.
119. Nabeshima, K.; Suzumiya, J.; Nagano, M.; Ohshima, K.; Toole, B. P.; Tamura, K.; Iwasaki, H.; Kikuchi, M. Emmprin, a cell surface inducer of matrix metalloproteinases (MMPs), is expressed in Tcell lymphomas. J. Pathol. 2004, 202(3), 341-351.
120. Nabeshima, K.; Inoue, T.; Shimao, Y.; Kataoka, H.; Koono, M. Cohort migration of carcinoma cells: differentiated colorectal carcinoma cells move as coherent cell clusters or sheets. Histol. Histopathol. 1999, 14(4), 1183-1197.
121. Nabeshima, K.; Komada, N.; Inoue, T.; Koono, M. A two dimensional model of cell movement. Well differentiated human rectal adenocarcinoma cells move as coherent sheets upon TPA stimulation. Pathol. Res. Pract. 1995, 191(1), 76-83.
122. Nabeshima, K.; Moriyama, T.; Asada, Y.; Komada, N.; Inoue, T.; Kataoka, H.; Sumiyoshi, A.; Koono, M. Ultrastructural study of TPA-induced cell motility: human well-differentiated rectal adenocarcinoma cellsmove as coherent sheets via localized modulation of cell-cell adhesion. Clin. Exp. Metast. 1995, 13(6), 499-508.
123. Sanders, D. S. A.; Bruton, R.; Darnton, S. J.; Casson, A. G.; Hanson, I.; Williams, H. K.; Jankowski, J. Sequential changes incadherin-catenin expression associated with the progression and heterogeneity of primary oesophageal squamous carcinoma. Int. J. Cancer 1998, 79(6), 573-579.
124. Li, G.; Satyamoorthy, K.; Herlyn, M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res. 2001, 61(9), 3819-3825.
125. Wong, A. S. T.; Pelech, S. L.; Woo, M. M. M.; Yim, G.; Rosen, B.; Ehlen, T.; Leung, P. C. K.; Auersperg, N. Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis? Oncogene 2001, 20(11), 1318-1328.
126. Nabeshima, K.; Inoue, T.; Shimao, Y.; Okada, Y.; Itoh, Y.; Seiki, M.; Koono, M. Front-cell-specific expression of membrane-type 1 matrix metalloproteinase and gelatinase A during cohort migration of colon carcinoma cells induced by hepatocytes growth factor/scatter factor. Cancer Res. 2000, 60(13), 3364-3369.
127. Deryugina, E. I.; Bourdon, M. A.; Reisfeld, R. A.; Strongin, A. Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res. 1998, 58(16), 3743-3750.
128. Murphy, G.; Gavrilovic, J. Proteolysis and cell migration: creating a path? Curr.Opin. Cell Biol. 1999, 11(5), 614-621.
129. Strongin, A. Y.; Collier, L.; Bannikov, G.; Marmer, B. L.; Grant, G. L.; Goldberg, G. I. Mechanism of cell surface activation of 72kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 1995, 270(10), 5331-5338.
130. Nabeshima, K.; Inoue, T.; Shimao, Y.; Kataoka, H.; Koono, M. TPA-induced cohort migration of well-differentiated human rectal adenocarcinoma cells: cells move in a RGD-dependent manner on fibronectin produced by cells, and phosphorylation of E-cadherin/catenin complex is induced independently of cell-extracellular matrix interactions. Virch. Arch. 1998, 433(3), 243-253.
131. Kalluri, R.; Weinberg, R. A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119(6), 1420-1428.
132. Lochter, A.; Galosy, S.; Muschler, J.; Freedman, N.; Werb, Z.; Bissell, M. J. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-tomesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J. Cell Biol. 1997, 139(7), 1861-1872.
133. Sternlicht, M. D.; Lochter, A.; Sympson, C. J.; Huey, B.; Rougier, J. P.; Gray, J. W.; Pinkel, D.; Bissell, M. J.; Werb, Z. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell, 1999, 98(2), 137-146.
134. Radisky, D. C.; Levy, D. D.; Littlepage, L. E.; Liu, H.; Nelson, C. M.; Fata, J. E.; Leak, D.; Godden, E. L.; Albertson, D. G.; Nieto, M. A.; Werb, Z.; Bissell, M. J. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature, 2005, 436(7047), 123-127.
135. Kaplan, R. N.; Riba, R. D.; Zacharoulis, S.; Bramley, A. H.; Vincent, L.; Costa, C.; MacDonald, D. D.; Jin, D. K.; Shido, K.; Kerns, S. A.; Zhu, Z.; Hicklin, D.; Wu, Y.; Port, J. L.; Altorki, N.; Port, E. R.; Ruggero, D.; Shmerkov, S. V.; Jensen, K. K.; Rafii, S.; Lyden, D. VEGFR1-positive hematopoietic bone marrow progenitors intiate the pre-metastatic niche. Nature, 2005, 438(7069), 820-827.
136. Boire, A.; Covic, L.; Agarwal, A.; Jacques, S.; Sherifi, S.; Kuliopulos, A. PAR1 is a matrix metalloproteinase-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005, 120(3), 303-313.
137. Scherer, R. L.; McIntyre, J. O.; Matrisian, L. M. Imaging matrix metalloproteinases in cancer. Cancer Metastasis Rev. 2008, 27(4), 679-690.
138. Overall, C. M.; Lopez-Otin, C. Strategies for MMP inhibition in cancer: innovations for the post trial era. Nat. Rev. Cancer, 2002, 2(9), 657-672.
139. Bloomston, M.; Zervos, E. E.; Rosemurgy, A. S. 2nd. Matrixmetalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann. Surg. Oncol. 2002, 9(7), 668-672.
140. Dorman, G.; Cseh, S.; Hajdu, I.; Barna, L.; Konya, D.; Kupai, K.; Kovacs, L.; Ferdinandy, P. Matrix metalloprotease inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs 2010, 70(8), 949-964.
141. Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295(5564), 2387-2392.
142. Nozawa, H.; Chiu, C.; Hanahan, D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl. Acad. Sci. USA 2006, 103(33), 12493-12498.
143. Witters, L.; Scherie, P.; Friedman, S.; Friedman, J.; Caulder, E.; Newton, R.; Lipton, A. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/new tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res. 2008, 68(17), 7083-7089.
144. Le MauxChansac, B.; Misse, D.; Richon, C.; Vergnon, I.; Kubin, M.; Sria, J. C.; Moretta, A.; Chouaib, S.; Mami-Chouaib, F. Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway. Int. Immunol. 2008, 20(7), 801-810.
145. Gondi, C. S.; Lakka, S. S.; Dinh, D. H.; Olivero, W. C.; Gujrati, M.; Rao, J. S. Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis andtumor growth. Neuron Glia Biol. 2004, 1(2), 165-176.
146. Song, X.; Wang, X.; Zhuo, W.; Shi, H.; Feng, D.; Sun, Y.; Liang, Y.; Fu, Y.; Zhou, D.; Luo, Y. The regulatory mechanism of extracellular Hsp90 (alpha) on matrix metalloproteinase-2 processing and tumor angiogenesis. J. Biol. Chem. 2010, 285(51), 40039-40049.
147. Stellas, D.; Hamidieh, A. E. I.; Patsavoudi, E. Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biol. 2010, 11(Jul 5), 51-60.
148. Atkinson, J. M.; Falconer, R. A.; Edwards, D. R.; Pennington, C. J.; Siller, C. S.; Shnyder, S. D.; Bibby, M. C.; Patterson, L. H.; Loadman, P. M.; Gill, J. H. Development of a novel tumor- targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases. Cancer Res. 2010, 70(17), 6902-6912.
149. Hatakeyama, H.; Akita, H.; Ishida, E.; Hashimoto, K.; Kobayashi, H.; Aoki, T.; Yasuda, J.; Obata, K.; Kikuchi, H.; Ishida, T.; Kiwada, H.; Harashima, H. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int. J. Pharma. 2007, 342(1-2), 194-200.
150. Olson, E. S.; Aguilera, T. A.; Jiang, T.; Ellies, L. G.; Nguyen, Q. T.; Wong, E.; Gross, L.; Tsien, R. Y. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr. Biol. (Camb.) 2009, 1(5-6), 382-393.
151. Whitney, M.; Crisp, J. L.; Olson, E. S.; Aguilera, T. A.; Gross, L. A.; Ellies, L. G.; Tsien, R. Y. Parallel in vivo and in vitro selection using phage display identifies protease-dependent tumor-targeting peptides. J. Biol. Chem. 2010, 285(29), 22532-22541.
152. Jang, J. H.; Kim, M. Y.; Lee, J. W.; Kim, S. C.; Cho, J. H. Enhancement of the cancer targeting specificity of buforin IIb by fusion with an anionic peptide via a matrix metalloproteinasecleavable linker. Peptides 2011, 32(5), 895-899.
153. Yang, M.D.; Lai, K.C.; Lai, T.Y.; Hsu, S.C.; Kuo, C.L.; Yu, C-S.; Lin, M.L.; Yang, J.S.; Kuo, H.M.; Wu, S.H.; Chung, J. P. G. Phenethyl isothiocyanate inhibits migration and invasion of human gastric cancer AGS cells through suppressing MAPK and NFkappaB signal pathways. Antican.Res. 2010, 30(6), 2135-2144.
154. Manikandan, P.; Murugan, R. S.; Priyadarsini, R. V.; Vinothini, G.; Nagini, S. Eugenol induces apoptosis and inhibits invasion and angiogenesis in a rat model of gastric carcinogenesis induced by MNNG. Life Sci. 2010, 86(25-26), 936-941.
155. Hwang, Y. P.; Jeong, H. G. Metformin blocks migration and invasion of tumor cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Calpha-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signalrelated kinase/activator protein-1. Brit. J. Pharmacol. 2010, 160(5), 1195-1211.
156. Evans, J. M.; Donnelly, L. A.; Emslie-Smith, A. M.; Alessi, D. R.; Morris, A. D. Metformin and reduced risk of cancer in diabetic patients. Brit. Med. J. 2005, 330(7503), 1304-1305.
157. Ganapathy, S.; Chen, Q.; Singh, K. P.; Shankar, S.; Srivastava, R. K. Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. PLoS One 2010, 5(12), e15627
158. Chia, J.-S.; Du, J.-L.; Hsu, W.-B.; Sun, A.; Chiang, C.-P.; Wang, W.-B. Inhibition of metastasis, angiogenesis, and tumor growth by Chinese herbal cocktail Tien-Hsien Liquid. BMC Cancer 2010, 10(Apr 30), 175.
159. Yang, C. M.; Liu, Y. Z.; Liao, J. W.; Hu, M. L. The in vitro and in vivo anti-metastatic efficacy of oxythiamine and the possible mechanism of action. Clin. Exp. Metastasis 2010, 27(5), 341-349.
160. Farabegoli, F.; Papi, A.; Orlandi, M. (-)-Epigallocathechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 famoxifen-resistant cells. Biosci. Rep. 2011, 31(2), 99-108.
161. Muscella, A.; Calabriso, N.; Vetrugno, C.; Urso, L.; Fanizzi, F. P.; De Pascali, S. A.; Marsigliante, S. Sublethal concentrations of the platinum(II) complex [Pt(O, O'-acac)(DMS) alter the motility and induce anoikis in MCF-7 cells. Br. J. Pharmacol. 2010, 160, (6) 1362-1377.
162. Karam, A. K.; Santiskulvong, C.; Fekete, M.; Zabih, S.; Eng, C.; Dorigo, O. Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. Cytoskeleton (Hoboken) 2010, 67(8), 535-544.
163. Schultz, J. D.; Rotunno, S.; Erben, P.; Sommer, J. U.; Anders, C.; Stern-Straeter, J.; Holheinz, R. D.; Hormann, K.; Sauter, A. Downregulation of MMP-2 expression due to inhibition of receptor tyrosine kinases by imatinib and carboplatin in HNSCC. Oncol.Rep.2011, 25(4), 1145-1151.
164. Camargo, C. A.; da Silva, M. E.; da Silva, R. A.; Justo, G. Z.; Gomes-Marcondes, M. C.; Aoyama, H. Inhibition of tumor growth by quercetin with increase of survival and prevention of cachexia in Walker 256 tumor-bearing rats. Biochem. Biophy. Res. Commun. 2011, 406(4), 638-642.
165. Yin, J H.; Shi, W. D.; Zhu, X, Chen, Z.; Liu, L. M. Qingyihuaji formula inhibits progress of liver metastasis from advanced pancreatic cancer xenograft by targeting to decrease expression of Cyr61 and VEGF. Integr.Cancer Ther. 2011 Mar. 7 [Epub ahead of print]
166. Chiou, Y. S.; Tsai, M. L.; Wang, Y. J.; Cheng, A. C.; Lai, W. M.; Badmaev, V.; Ho, C. T.; Pan, M. H. Pterostilbene inhibits colorectal aberrant crypt foci (ACF) and colon carcinogenesis via suppression of multiple signal transduction pathways in azoxymethane-treated mice. J. Agric. Food Chem. 2010, 58(15), 8833-8841.
167. Sun, Z. J.; Yu, T.; Chen, J. S.; Sun, X.; Gao, F.; Zhao, X. L.; Luo, J. Effects of ulinastatin and cyclophosphamide on the growth of xenograft breast cancer and expression of CXC chemokine receptor 4 and matrix metalloproteinase-9 in cancers. J. Int. Med. Res. 2010, 38(3), 967-976.
168. Kamaraj, S.; Anandakumar, P.; Jagan, S.; Ramakrishnan, G.; Devaki, T. Modulatory effect of hesperidin on benzo(a)pyrene induced experimental lung carcinogenesis with reference to COX-2, MMP-2 and MMP-9. Eur. J. Pharmacol. 2010, 649(1-3), 320-327.
169. Zhang, L. J.; Chen, L.; Lu, Y.; Wu, J. M.; Xu, B.; Sun, Z. G.; Zheng, S. Z.; Wang, A. Y. Danshensu has anti-tumor activity in B16F10 melanoma by inhibiting angiogenesis and tumor cell invasion. Eur. J. Pharmacol. 2010, 643(2-3), 195-201.
170. Pitchakam, P.; Ogawa, K.; Suzuki, S.; Takahashi, S.; Asamoto, M.; Chewonarin, T.; Limtrakul, P.; Shirai, T. Momordica charantia leaf extract Suppresses rat prostate cancer progression in vitro and in vivo. Cancer Sci. 2010, 101(10), 2234-2240.
171. Lin, W. L.; Liang, W. H.; Lee, Y. J.; Chuang, S. K.; Tseng, T. H. Antitumor progression potential of caffeic acid phenethyl ester involving p75(NTR) in C6 glioma cells. Chem. Biol. Interact. 2010, 188(3), 607-615.
172. Hamsa, T. P.; Kultan, G. Harmine inhibits tumour specific neovessel formation by regulating VEGF, MMP, TIMP and proinflammatory mediators both in vivo and in vitro. Eur. J. Pharmacol. 2010, 649(1-3), 64-73.
173. Sil, H.; Sen, T.; Moulik, S.; Chatterjee, A. Black tea polyphenol (theaflavin) downregulates MMP-2 in human melanoma cell line A375 by involving multiple regulatory molecules. J. Environ. Pathol. Toxicol. Oncol. 2010, 29(1), 55-68.
174. Ghosh, R.; Graham, H.; Rivas, P.; Tan, X. J.; Crosby, K.; Bhaskaran, S.; Schoolfield, J.; Banu, J.; Fernandes, G.; Yeh, I-T.; Kumar, A. D. Phellodendron Amurense bark extract prevents progression of prostate tumors in transgenic adenocarcinoma of mouse prostate: potential for prostate cancer management. Anticancer Res. 2010, 30(3), 857-866.
175. Hwang, E.-S.; Park, K.-K. Magnolol suppresses metastasis via inhibition of invasion, migration, and matrix metalloproteinase-2/-9 activities in PC-3 human prostate carcinoma cells. Biosci. Biotechnol. Biochem. 2010, 74(5), 961-967.
176. Shin, D. Y.; Kim, G.-Y.; Kim, J.-I.; Yoon, M. K.; Kwon, T. K.; Lee, S. J.; Choi, Y.-W.; Kang, H. S.; Yoo, Y. H.; Choi, Y. H. Antiinvasive activity of diallyl disulfide through tightening of tight junctions and inhibition of matrix metalloproteinase activities in LNCaP prostate cancer cells. Toxicol. In Vitro 2010, 24(6), 1569-1576.
177. Deziel, B. A.; Patel, K.; Neto, C.; Gottschall-Pass, K.; Hurta, R. A. Proanthocyanidins from the American Cranberry (Vaccinium macrocarpon) inhibit matrix metalloproteinase-2 and matrix metalloproteinase-9 activity in human prostate cancer cells via alterations in multiple cellular signaling pathways. J. Cell Biochem. 2010, 111(3), 742-754.
178. Wang, Z.; Ahmad, A.; Beejee, S.; Azmi, A.; Kong, D.; Li, Y.; Sarkar, H. FoxM1 is a novel target of a natural agent in pancreatic cancer. Pharm. Res. 2010, 27(6), 1159-1168.
179. Woenne, E. C.; Lederle, W.; Zwick, S.; Palmowski, M.; Krell, H.; Semmler, W.; Mueller, M. M.; Kiessling, F. MMP inhibition blocks fibroblast-dependent skin cancer invasion, reduces vascularization and alters VEGF-A and PDGF-BB expression. Anticancer Res. 2010, 30(3), 703-712.
180. Wang, L.; Ling Y.; Chen, Y.; Li, C.-L.; Feng, F.; You, Q.-D.; Lu, N.; Guo, Q.-L. Flavonoid baicalein suppresses adhesion, migration and invasion of MDA-MB-231 human breast cancer cells. Cancer Lett. 2010, 297(1), 42-48.
181. Shahani, K.; Kumar, S.; Swaminathan, K.; Freeman, D.; Blum, A.; Ma, L.; Panyam, J. Injectable sustained release microparticles of curcumin: a new concept for cancer chemoprevention. Cancer Res. 2010, 70(11), 4443-4452.
182. Sen, T.; Dutta, A.; Chatterjee, A. Epigallocathechin-3-gallate (EGCG) downregulates gelatinase-B (MMP-9) by involvement of FAK/ERK/NFkappaB and AP-1 in the humanbreast cancer cell line MDA-MB-231. Anticancer Drugs 2010, 21(6), 632-644.
183. Lin, M.-L.; Lu, Y.-C.; Chung, J.-G.; Wang, S.-G.; Lin, H.-T.; Kang, S.-E.; Tang, C.-H.; Ko, J.-L.; Chen, S.-S. Down-regulation of MMP-2 through the p38 MAPK-NF-kappaB-dependent pathway by aloe-emodin leads to inhibition of nasopharyngeal carcinoma cell invasion. Mol. Carcinog. 2010, 49(9), 783-797.
184. Lee, Y. R.; Noh, E. M.; Oh, H. J.; Hur, H.; Kim, J. M.; Han, J. H.; Kwang, J. K.; Park, J. W.; Youn, H. J.; Jung, S. H.; Kim, B. S.; Jung, J. Y.; Lee, S. H.; Park, C. S.; Kim, J. S. Dihydroavenanthramide D inhibits human breast cancer cell invasion through suppression of MMP-9 expression. Biochem. Biophys. Res. Commun. 2011, 405(4), 552-7.
185. Kapral, M.; Wawszczyk, J.; Jurzak, M.; Dymitruk, D.; Weglarz, L. Evaluation of the expression of metalloproteinase 2 and 9 and their tissue inhibitors in colon cancer cells treated with phytic acid. Acta Pol. Pharm. 2010, 67(6), 625-9.
186. Hwang, Y. P.; Yun, H. J.; Choi, J. H.; Han, E. H.; Kim, H. G.; Sonh, G. Y.; Known, K. I.; Jeong, T. C.; Jeong, H. G. Suppression of EGF-induced tumor cell migration and matrix metalloproteinase-9 expression by capsaicin via the inhibition of EGFR-mediated FAK/Akt, PKC/Raf/ERK, p38 MAPK, and AP-1 signaling. Mol. Nutr. Food Res. 2011, 55(4), 594-605.
187. Chien, S. T.; Lin, S. S.; Wang, C. K.; Lee, Y. B.; Chen, K. S.; Fong, Y.; Shin, Y. W. Acacetin inhibits the invasion and migration of human non-small cell lung cancer A549 cells by suppressing the p38α MAPK signaling pathway. Mol. Cell Biochem. 2011, 350(1-2), 135-148.
188. Hwang, Y. P.; Yun, H. J.; Kim, H. G.; Han, E. H.; Choi, J. H.; Chung, Y. C.; Jeong, H. G. Suppression of phorbol-12-myristate-13-acetate-induced tumor cell invasion by piperine via the inhibition of PKCα/ERK1/2-dependent matrix metalloproteinase-9 expression. Toxicol. Lett 2011, 203(1): 9-19.
189. Man, S.; Gao, W.; Zhang, Y.; Liu, Z.; Yan, L.; Huang, L.; Liu, C. Formosanin C-inhibited pulmonary metastasis through repression of matrix metalloproteinases on mouse lung adenocarcinoma. Cancer Biol. Ther. 2011, 11(6), 592-598.
190. Wilken, R.; Veena, M. S.; Wang, M. B.; Srivatsan, E. S. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol. Cancer 2011, 10(Feb 7), 12.
191. Mao, L.; Yuan, L.; Slakey, L. M.; Jones, F. E.; Burow, M. E.; Hill, S. M. Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res. 2010, 12(6), R107(1-14).
192. Han, H.; Du, B.; Pan, X.; Liu, J.; Zhao, Q, Lian, X.; Qian, M.; Liu, M. CADPE inhibits PMA-stimulated gastric carcinoma cell invasion and matrix metalloproteinase-9 expression by FAK/MEK/ERK-mediated AP-1 activation. Mol. Cancer Res. 2010, 8(11), 1477-1488.
193. Hwang, Y. P.; Oh, K. N.; Yun, H. J.; Jeong, H. G. The flavonoids apigenin and luteolin suppress ultraviolet A-induced matrix metalloproteinase-1 expression via MAPKs and AP-1-dependent signaling in HaCaT cells. J. Dermatol. Sci. 2011, 61(1), 23-31.
194. Son, S. H.; Park, K. K.; Park, S. K.; Kim, Y. C.; Kim, Y. S.; Lee, S. K.; Chung, W. Y. Decursin and Decursinol from Angelica gigas inhibit the lung metastasis of murine colon carcinoma. Phytother. Res. 2010, Dec. 16. doi: 10. 1002/ptr.3372. [Epub ahead of print]
195. Shin, D. Y.; Lu, J. N.; Kim, G.-Y.; Jung, J. M.; Kang, H. S.; Lee, W. S.; Choi, Y. H. Anti-invasive activities of anthocyanins through modulation of tight junctions and suppression of matrix metalloproteinase activities in HCT-116 human colon carcinoma cells. Oncol. Rep. 2011, 25(2), 567-572.
196. Hwang, S. T.; Pang, J. H.; Yang, R. C. Anti-cancer effects of Phyllanthus Urinaria and relevant mechanisms. Chang Gung Med. J. 2010, 33(5), 477-487.
197. Chiu, C. C.; Huang, K. J.; Wang, H. M.; Chang, K. F.; Chou, C. K.; Chang, F. R.; Chong, I. W.; Fang, K.; Chen, J. S.; Chang, H. W.; Wu, Y. C. Goniothalamin inhibits growth of human lung cancer cells through DNA damage, apotosis, and reduced migration ability. J. Agric. Food Chem. 2011, 59(8), 4288-4293.
198. Funel, N.; Costa, F.; Pettinari, L.; Taddeo, A.; Sala, A.; Chriva-Internati, M.; Cobos, E.; Colombo, G.; Mizani, A.; Campari, D.; Dalle-Donne, I.; Gagliano, N. Ukrain affects pancreas cancer cell phenotype in vitro by targeting MMP-9 and intra-/extracellular SPARC expression. Pancreatology 2010, 10(5), 545-552.
199. Yang, X.; Zhang, Y.; Wang, S.; Shi, W. Effect of fasudil on growth, adhesion, invasion, and migration of 95D lung carcinoma cells in vitro. Can. J. Physiol. Pharmacol. 2010, 88(9), 874-879.
200. Lai, K. C.; Hsu, S. C.; Yang, J. S.; Kuo, C. L.; Ip, S. W.; Lai, T. Y.; Lin, S. Y.; Huang, C. C.; Kuo, S. C.; Wood, W. G.; Chung, J. G. 2-(3-Methoxyphenyl)-6, 7-methylenedioxoquinolin-4-one, a novel synthetic compound, inhibited migration and invasion in TSGH8301 human bladder cancer cells. Hum. Exp. Toxicol. 2011, 30(8), 1045-1052.
201. Lee, H. S.; Na, M. H.; Kim, W. K. Alpha-Lipoic acid reduces matrix metalloproteinase activity in MDA-MB-231 human breast cancer cells. Nutr. Res., 2010, 30(6), 403-409.
202. Yang, D.; Gu, T.; Wang, T.; Tang, Q.; Ma, C. Effects of osthole on migration and invasion in breast cancer cells. Biosci. Biotechnol. Biochem. 2010, 74(7), 1430-1434.
203. Lee, E. J.; Kim, W. J.; Moon, S. K. Cordycepin suppresses TNFalpha-induced invasion, migration and matrix metalloproteinase-9 expression in human bladder cancer cells. Phytother. Res. 2010, 24(12), 1755-1761.
204. Huang, Y. T.; Lai, P. C.; Wu, C. C.; Cheng, C. C., Chiu, T. H. TrkB antibody elicits cytotoxicity and suppresses migration/invasion of transitional cell carcinoma cells. Int. J. Oncol. 2010, 37(4), 943-949.
205. Miao, Y.; Zhang, Y.; Wan, H.; Chen, L.; Wang, F. GABA-receptor agonist, Propofol inhibits invasion of colon carcinoma cells. Biomed. Pharmacother. 2010, 64(9), 583-588.
206. Okazaki, I.; Sugita, M.; Matsuki, H.; Billah, S. M. B.; Watanabe, T. Additional candidates to conventional genes susceptible forlung cancer and changing trend in Japan. Oncol. Rep. 2010, 23(6), 1493-1500.
207. Baumgart, A.; Seidi, S.; Vlachou, P.; Michel, L.; Mitova, N.; Schatz, N.; Specht, K.; Koch, I.; Schuster, T.; Grunder, R.; Kremer, M.; Fend, F.; Siveke, J. T.; Peschel, C.; Duyster, J.; Dechow, T. ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer. Cancer Res. 2010, 70(13), 5368-5378.
208. Debret, R.; Brassart-Pasco, S.; Lorin, J.; Martoriati, A.; Deshorgue, A.; Maquart, F. X.; Homebeck, W.; Rahman, I.; Antonicelli, F. Ceramide inhibition of MMP-2 expression and human cancer bronchial cell invasiveness involve decreased histone acetylation. Biochim. Biophy. Acta 2008, 1783(10), 1718-1727.
209. Rangwala, F.; Omenetti, A.; Diehl, A. M. Cancer stem cells: repair gone away? J. Oncol., 2011, Article ID 465343, 11 pages, doi:10.1155/2011/465343